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Between 2001 and 2012, the number of unrelated donors regis-tered worldwide increased from 7 to 21 million, and the numberof public cord blood units increased to over 500,000. We
addressed the question of whether this expansion resulted in higher
percentages of patients reaching transplantation. Unrelated donor
searches were evaluated for 3,124 eligible patients in the Netherlands
in two cohorts (2001-2006, n=995; 2007-2012, n=2129), comparing
results for patients of Northwestern European and non-Northwestern
European origin. Endpoints were ‘donor found’ and ‘transplantation
reached’. The substantial growth of the donor inventory over the peri-
od studied did not increase the median number of potential unrelated
donors (n=7) for non-Northwestern European patients, but almost dou-
bled the number for Northwestern European patients from 42 to 71.
Before and after 2007, an unrelated donor or cord blood was identified
for 91% and 95%, respectively, of Northwestern European patients and
for 65% and 82% of non-Northwestern European patients (P<0.0001).
Non-Northwestern European patients more often needed a cord blood
transplant. The degree of HLA matching was significantly lower for
non-Northwestern European patients (P<0.0006). The time needed to
identify a donor decreased for both populations. The percentage of
Northwestern European patients reaching transplantation increased
from 77% to 83% and for non-Northwestern European patients from
57% to 72% (P=0.0003). The increase of the global inventory resulted
in more transplants for patients lacking a family donor, although the
quality and quantity of (potential) haematopoietic cell grafts for
patients of a non-Northwestern European descent remained inferior,
indicating the need for adaptation of recruitment.
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ABSTRACT
Introduction
Allogeneic hematopoietic progenitor cell transplanta-
tion plays an important role in treatment of hemato-
oncological diseases. For patients lacking a matched
related donor, an unrelated donor (UD) or cord blood
unit (CBU) may provide a valuable alternative.
Alternative donors are identified through registries of
volunteer unrelated donors or public cord blood banks.
In the past decade, the identification and availability of
UD and UCB have improved. Bone Marrow Donors
Worldwide (BMDW), the file of registered unrelated
donors, almost tripled (from 7.4 million donors in 2001
to over 21 million in December 2012), while the invento-
ry of unrelated CBU grew from 87,000 in 2001 to over
500,000.1 To date (2016) the number of registered donors
has increased to over 27 million, and currently over
650.000 CBU are registered. Increased knowledge of the
HLA system, more well-typed donors, and the availabil-
ity of several search-related software tools2-5 have facili-
tated and speeded up the efficiency of the search
process.6-8 Simultaneously searching for a back-up donor
can minimize the delay if a donor is unexpectedly not fit
or unavailable to donate.9 Given these recent improve-
ments, we set out to address the questions of whether a
higher percentage of patients in need of an UD/CBU may
actually reach transplantation nowadays, whether the
time needed to identify an UD/CBU has decreased, and
whether possible factors can be identified for potential
improvement. We addressed the questions in a large
cohort of 3,365 consecutive UD searches performed
between 2001-2012 in the Netherlands, including search-
es for Dutch patients of Northwestern European (NWE)
and non-Northwestern European (non-NWE) descent. 
Methods
The patients and donor searches 
Europdonor Foundation, the Dutch Stem cell donor registry,
coordinates the UD searches in the Netherlands, serving a popula-
tion of 16.8 million inhabitants. There were eight adult and two
pediatric stem cell transplantation units in 2012 in the
Netherlands, and the number of new searches increased to
approximately 500 annually. All UD and CBU searches performed
from 2001 until 2012 for the patients of all Dutch transplantation
centers were included (n=3,365, Figure 1) for the initial ‘donor
found’ analysis, and divided into two periods: cohort I, 2001-2006
(n=1,093) and cohort II, 2007-2012 (n=2,272). Patients for whom a
search was cancelled in less time than the median search time for
the given year, and for whom no donor was yet identified were
excluded for the ‘donor found’ analysis (cohort I, n=75; cohort II,
n=131), leaving 3,124 evaluable search cases. Each cohort was
split according to NWE and non-NWE descent. Patients were
assigned to NWE or non-NWE background based upon self-iden-
tified descent.10 Descendants from the Netherlands, Germany,
Belgium, Luxembourg, Great Britain, Ireland, and Scandinavia
were considered NWE. The non-NWE group consisted of
patients with self-reported genetic ancestry in Northern Africa
(n=51), Sub-Saharan Africa (n=22), Turkey (n=87), Asia (n=54),
Eastern Europe (n=4), Hispanic (n=9), or mixed (n=125). Patients
with unknown ethnic background (n=35, of whom 14 reached
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Figure 1. Overview of inclusion/exclusion in different stages of the search process. NWE: Northwestern European; non-NWE: non-Northwestern European; DF: donor
found; CB: cord blood; RT: reached transplantation with unrelated donor or CB. *Patients for whom the procedure was cancelled for reasons not related to the search
process were excluded (see Methods section).
transplantation) were excluded. Searches for combined
donor/CBU and CBU-only and searches for NWE and non-NWE
patients were analyzed separately. 
Diagnoses were described in broad groups (Table 1). Overall, a
donor was found for 2,861 (91%) of the patients (Table 2). For the
subsequent analysis of ‘reaching transplantation’ we excluded 288
patients from the original cohorts I (n=89/995) and II (=199/2,129)
for whom a donor was found but transplantation was cancelled for
reasons not related to the search process (Figure 1). These reasons
included never having reached remission/refractory disease
(n=100), alternative therapy chosen (e.g. anti-thymocyte globulin
for severe aplastic anemia, or randomized to a non-transplant arm
in a study, n=88), autologous hematopoietic stem cell transplant
(n=5), (extended) family donor available (n=23), indication
changed/good clinical condition (n=27), and patient withdrawal
(n=45). This left 2,836 patients for whom a successful search was
performed (788 NWE and 118 non-NWE patients in cohort I, and
1,720 NWE and 210 non-NWE patients in cohort II).
Search strategies
The basis for the UD/CBU search has been described else-
where11,12 and was adjusted to new insights and better quality of
the donor pool. Each new search, irrespectively of whether it was
for an UD or CBU, started with estimation of the likelihood of
finding an acceptable donor, taking into consideration the match-
grade or haematopoietic cell source preferences of a center. These
results were communicated to the center so that, in cases for
which it was unlikely that an acceptable donor would be found,
search strategies or treatment options could be adjusted to avoid
unnecessary delay. 
The search profile for an UD was based upon confirmed HLA-
typing of the patient (HLA-A, B, C, DRB1, DQB1 high resolution),
including a review of family typing, haplotype frequencies, allele
frequencies, HLA-B/C-associations, and HLA-DRB1/DQB1 asso-
ciations. Ethnic background and results of the BMDW regular
match (mismatch runs if applicable) were taken into considera-
tion. When appropriate, advice for a concurrent donor search
within the extended family search was given.12 A 10/10 or 9/10
HLA-matched donor was usually preferred; however, in some
transplant protocols (e.g. with reduced intensity conditioning)
mismatched donors were not acceptable. 
The search profile for a CBU was based on HLA-A, -B serolog-
ical (split) level, and -DRB1 at high resolution and the minimum
total nucleated cell count based on the recipient’s body weight, in
accordance with local protocols.13 If no 6/6 or 5/6 mismatched
units with sufficient total nucleated cells were identified, a run for
two mismatches was performed, for both single and double CBU
searches. 
In the selection of donors for verification typing, non-HLA fac-
tors (age, gender, ABO group, cytomegalovirus status, previous
donation) were considered. Verification typing of a prospective
UD was performed for HLA-A, B, C, DRB1, DQB1 high resolution
by the center; for the selection of a CBU the minimum HLA typing
requirements were HLA-A and –B on a serological split level and
HLA-DRB1 at high resolution, usually performed upon request by
the cord blood bank. In this study, for a number of patients, HLA-
C was not typed due to local policies. Match-grade for these pairs
(71 in cohort I and 129 in cohort II) were considered ‘unknown’.
Definitions
Donor found means that there was a donor or CBU meeting the
valid HLA matching criteria of the center at that time. Length of
search refers to the interval in days from the start of the search to
the time of identifying an acceptable donor or CBU. If a search
was cancelled after the median time necessary for a search in that
particular year, the outcome was considered No donor found: the
search remained included in the No donor found-group.  
Statistical analysis
Statistical analyses were performed using R version 2·15·1 (R
Foundation for Statistical Computing). We used the chi square
test, Fisher exact test (two-tailed) and Wilcoxon rank sum test to
measure association and differences and the Pearson product-
moment to determine correlations. A P-value of 0.05 or less was
considered statistically significant.
Institutional Review Board approval
Dutch Transplant Centers are responsible for obtaining
informed consent for (anonymized) data analysis and data
exchange from all patients referred for UD searches. Additional
Institutional Review Board approval to perform this study was not
necessary.
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Table 1. Baseline characteristics of 2772 NWE and 352 non-NWE patients in the two search periods.
2001-2006 2007-2012 P 2001-2006 2007-2012 P
NWE NWE non-NWE non-NWE
Total n. of patients 871 1901 124 228
< 16 years; n (%)* 135 (15.5) 139 (7.3) P<0.0001 41 (33.1) 66 (28.9) n.s.
Median age (years, range)** 38.5 (0.1-67.1) 51.5 (0.1-79.7) P<0.0001 13.8 (0.1-65.7) 19.9 (0.1-67.3) P=0.002
Median age < 16 years (years) 6.4 6.3 n.s. 4.5 5.3 n.s.
Median age > 16 years (years) 44.3 54 P<0.0001 30.6 42.0 P=0.01
Male, n (%)* 545 (62.6) 1131 (59.5) n.s. 82 (66.1) 141 (61.8) n.s.
Deviation from 50:50 ratio*** P<0.0001 P<0.0001 P<0.0001 P<0.0001
Diagnosis n. (%)*
Acute leukemia 341 (39.2) 885 (46.6) P=0.0003 50 (40.3) 85 (37.3) n.s.
Chronic leukemia 123 (14.1) 195 (10.3) P=0.0038 10 (8.1) 16 (7.0) n.s.
Myelodysplastic syndrome 124 (14.2) 241 (12.7) n.s. 11 (8.9) 19 (8.3) n.s.
Lymphoma 109 (12.5) 227 (11.9) n.s. 4 (3.2) 19 (8.3) n.s.
Other malignant diseases 57 (6.5) 190 (10.0) P=0.0032 2 (1.6) 8 (3.5) n.s.
Non-malignant disease 117 (13.4) 163 (8.6) P=0.0001 47 (37.9) 81 (35.5) n.s.
Acute leukemia includes acute lymphoblastic leukemia and acute myeloid leukemia; chronic leukemia includes chronic lymphocytic leukemia and chronic myeloid leukemia; Other
malignant diseases include plasma cell disorders, Non-malignant diseases include bone marrow failure and inborn errors. *Fisher exact test; **Wilcoxon rank sum test; ***chi square
test.
Results
The baseline characteristics of NWE (n=2,772) and non-
NWE (n=352) patients are presented in Table 1. The distri-
bution of NWE and non-NWE patients did not differ sig-
nificantly over time between the two cohorts (13% non-
NWE in cohort I, and 11% non-NWE in cohort II). Data
for non-NWE and mixed background patients were also
analyzed separately, but showed similar outcome results
and no significant differences between groups. The medi-
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Table 2. Characteristics of the search process and reaching transplantation for NWE and non-NWE patients in the two periods. 
2001-2006 2007-2012 P 2001-2006 2007-2012 P
NWE NWE non-NWE non-NWE
Total n. of patients 871 1901 124 228
HLA-A/B/DR- matches in BMDW* 42 71 P=0.0002 7 7 n.s.
median number (range) (0-17851) (0-37618) (0-655) (0-1841)
Search performed, n (%)**
Donor/CBU search, n 862 1819 115 187
CBU only search, n (%) 9 (1) 82 (4.5 ) P<0.0001 9 (7.3) 41 (18) P=0.006
Samples requested, n* 3889 8450 449 813
Median (range) 5 (1-18) 4 (1-27) P<0.0001 4 (1-17) 4 (1-14) n.s.
Samples received, n (%) 2464 (63.4) 5458 (65) 240 (53.5) 399 (49.1) n.s.
Median 4 3 P<0.0001 3 2
Donor/CBU found, n (%)** 788 (90.5) 1807 (95.1) P<0.0001 80 (64.5) 186 (81.6) P=0.0007
Donor, n (%) 756 (86.8) 1624 (85.4) n.s. 58 (46.8) 112 (49.) n.s.
CBU, n (%) 32 (3.7) 183 (9.6) P<0.0001 22 (17.7) 74 (32.5) n.s.
No donor found, n 83 94 P<0.0001 44 42 P=0.0007
Donor not acceptable, n 7 26 2 1
Match-grade donors #,**
10/10, n (%) 460 (64.2) 1158 (68.8) P=0.03 23 (28.8) 46 (25.6) n.s.
9/10, n (%) 193 (26.9) 326 (19.4) P=0.0003 28 (35.0) 59 (32.8) n.s.
<9/10, n (%) 32 (4.5) 17 (1.0) 7 (8.8) 1 (0.6)
Cord blood, n (%) 32 (4.5) 183 (10.9) P=0.0001 22 (27.5) 74 (41.1) n.s.
Match-grade unknown, n (%) 71 (9.0%) 123 (6.8%) n.a. 6 (3.2%)
Donor age, median (range), years 34 (18-58) 35 (18-59) n.s. 34 (30-57) 37 (19-57) n.s.
Donor gender: male, n (%) 361 (63.2) 753 (60.3) n.s. 21 (48.8) 43 (52.4 n.s.
Sex matched, n (%) 365 (63.9) 871 (69.8) 23 (53.5) 42 (51.2)
Sex mismatched, n (%)** 206 (36.1) 377 (30.2) 0.01 20 (46.5) 40 (48.8) n.s.
• Male patient – female donor, n (%) 98 (17.2) 192 (15.4) n.s. 16 (37.2) 25 (30.5) n.s.
• Female patient – male donor, n (%) 108 (18.9) 185 (14.8) 0.02 4 (9.3)) 15 (18.3) n.s.
CMV status known, n. of pairs 381 1126 31 70
Matched (%) 237 (62.2) 817 (72.5) 21 (67.7) 49 (70.0)
CMV mismatched, n (%)** 144 (37.8) 309 (27.5) P=0.0002 10 (32.3) 21 (30.0) n.s.
• Pat. negative – donor positive, n (%) 51 (13.4) 122 (9.9) P=0.02 1 (3.2) 6 (8.6) n.s.
• Pat. positive – donor negative, n (%) 93 (24.4) 187 (16.6) P<0.0001 9 (29.1) 15 (21.4) n.s.
Length of search in days*
Start-donor found, median (range) 43 (2-393) 34 (1-276) P<0.0001 56 (7-123) 36 (1-290) P=0.0005
Excluded, n** 83 181 n.s. 6 18 n.s.
Included for reaching transplant analysis, n 788 1720 118 210
Reaching transplant, n (%)** 609 (77.3) 1425 (82.8) P=0.001 67 (56.8) 151 (72.0) P=0.007
• UD BM/PBSC, n (%) 571 (93.8) 1248 (87.6) P<0.0001 43 (64.2) 82 (54.3) n.s.
• CBU, n (%) 28 (4.6) 169 (11.6) P<0.0001 19 (28.4) 62 (41.1) n.s.
• Alternative family donor, n (%) 10 (1.6) 8 (0.8) P=0.03 5 (7.4) 7 (4.6) n.s.
With back-up donor/CBU, n (%) 68 (10.8) 157 (11.1) n.s. 2 (3.0) 13 (9.0) n.s.
Time to transplantation in days
Donor found – infusion 68 54 P<0.0001 48 53 P<0.0001
Start – infusion 113 91 P<0.0001 109 92 P=0.0008
• If CBU 102 85 P<0.0001 91 81 P<0.0001
Transplant with back-up donor (%) 68 (11.4) 157 (11.1) n.s. 2 (3.3) 13 (9.0) P=0.01
UD transplant cancelled, n (%)** 179 (22.1) 275 (16.0) 44 (37.3) 51 (24.3)
Clinical deterioration/died, n (%) 111 (63.8) 197 (71.6) P=0.03 17 (38.6) 24 (47.0) n.s.
Donor deferred, no back up, n (%) 51 (29.3) 68 (24.7) n.s. 27 (61.4) 27 (53.0) n.s.
Alternative therapy, n (%) 17 (6.9) 10 (3.7) P=0.01
CMV: cytomegalovirus; BM: bone marrow; PBSC: peripheral blood stem cells. *Fisher exact test; **Wilcoxon rank sum test; ***chi square test. #Match-grade for 71 patient
donor pairs in cohort I and 129 in cohort II were considered unknown due to incomplete typing.
an age of patients increased significantly over time, mainly
due to more elderly NWE patients. Non-NWE patients
remained significantly younger than NWE patients in both
periods (P<0·0001). Indications for transplantation
changed over time. The proportion of NWE patients with
chronic myeloid leukemia (P=0.0001) and inborn errors
(P=0.0003) decreased while the proportion of (elderly)
NWE patients with acute myeloid leukemia (P<0.0001)
and plasma cell malignancies (P=0.002) increased signifi-
cantly. The distribution of ethnic backgrounds of non-
NWE patients in cohorts I and II was similar. 
The characteristics of the search process are reported in
Table 2. The median number of potential donors increased
from 42 to 71 only for NWE patients (P=0.004) and
remained at seven for non-NWE patients. A preferred
CBU-only search was significantly more often performed
for non-NWE patients (P<0·0001, Table 3). 
Donor found 
A donor was found for 2,861 patients (91%).
Significantly more UD/CBU were found in cohort  II
(P<0.0001) for both NWE and non-NWE patients (Table
2). In cohort I, an UD/CBU was identified for 91% of
NWE patients and 65% of non-NWE patients. In cohort II,
an UD/CBU was identified for 95% of NWE and 82% of
non-NWE patients. Cord blood as an alternative
haematopoietic cell source was needed more frequently
for non-NWE patients in both cohorts (P<0.0001),
although better matched (6/6) units were more often
found for NWE patients (P<0.002, Online Supplementary
Data).The amount of CBU identified for non-NWE
patients almost doubled over time (18%-33%).
Grade of HLA-matching and aspects 
of non-HLA-matching 
Major differences in match-grade were observed
between NWE and non-NWE patients. As far as concerns
non-NWE patients, fewer 10/10 HLA-matched or 9/10
HLA-matched donors were identified in cohort II than in
cohort I. A ≥9/10 donor was found for at least 91% of
NWE patients in cohort I and 88% in cohort II, compared
to 64% of non-NWE patients in cohort I and 58% non-
NWE patients in cohort II (Table 2). 
The median time to identify a donor in a combined
donor/CBU search for NWE patients was 43 days in
cohort I and 34 days in cohort II. The same improvement
was also seen for non-NWE patients (median of 56 and 36
days in cohort I and II, respectively, Table 3).
A CBU-only search was performed upon request of the
centers for 18 patients in cohort I (2%) and 123 patients in
cohort II (6%). Preferred CBU-only searches were per-
formed significantly more often for non-NWE patients in
both cohorts. A preferred CBU search, despite the avail-
ability of a fully matched UD, was performed for a few
non-NWE patients (1 and 2 patients in cohort I and II,
respectively) and some NWE patients (5 and 17 patients in
cohort I and II, respectively). 
Other characteristics that may affect transplant out-
come, such as donor-recipient gender disparity, reduced
over time for NWE patients but not for non-NWE patients
in cohort II. Cytomegalovirus status mismatches between
the recipient-donor pairs decreased significantly for NWE
patients but not for non-NWE patients.
The donor searches for the patients excluded from the
‘reached transplantation’ analysis (89 in cohort I and 199
in cohort II, see Methods section) did not differ in length
(median 42 days and 35 days, respectively). No acceptable
UD/CBU was identified for 127/995 patients (13%) in
cohort I and 136/2124 (6%) patients in cohort II. The
median search time was longer for these patients than
those in the ‘donor found’ group (P<0·0001, data not
shown). 
Reaching transplantation
Despite a successful donor search, Transplant Centers
cancelled procedures for 89 patients in cohort I and 199
patients in cohort II, because the patients clinically deteri-
orated or died (Table 2). There was no correlation
between length of search and whether or not a transplant
was actually performed. The time from starting the search
to transplantation was significantly shorter for patients
receiving a cord blood graft in cohort II (P=0.0001). The
percentage of transplanted patients increased significantly
over time, with NWE patients more often reaching their
S.M. van Walraven et al.
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Table 3. Major differences between results for NWE and non-NWE patients in the two periods (I: 2001-2006, II: 2007-2012). 
NWE I non-NWE I P NWE II non-NWE II P
Median age (years)* 38.5 13.8 P<0.0001 51.5 19.9 P<0.0001
Diagnosis (%)**
Acute myeloid leukemia 23.8 20.2 n.s. 33.9 21.5 P<0.0001
Plasma cell dyscrasias 5.9 0.8 P=0.0153 9.3 3.5 P=0.0018
Non-malignant disease 8.8 32.3 P<0.0001 5.1 27.6 P<0.0001
Median donors in BMDW (n)* 42 7 P<0.003 71 7 P<0.0006
CBU only search (%)** 1 7.3 P<0.0001 4.4 41 P<0.0001
Samples received for CT (%)* 63 53 P=0.05 65 49 P<0.0001
Length of search (days) 43 56 P=0.013 34 36 P=0.02
Donor/CBU found (%)*** 90.5 64.5 P<0.0001 95.1 81.2 P<0.0001
10/10 (%) 64.2 28.8 P<0.0001 68.8 25.6 P<0.0001
9/10 (%) 26.9 35 P<0.02 19.4 32.8 n.s.
CB as stem cell source (%) 4.7 27.6 P<0.0001 10.1 39.8 P<0.0001
Reaching transplantation (%)** 77.3 56.8 P<0.0041 82.2 72.0 n.s.
*Wilcoxon rank-sum test; **Fisher exact test; CT: confirmatory typing; CB. cord blood.
intended transplantation. In total 77% (609/788) NWE and
57% (67/118) non-NWE eligible patients in cohort I and
82% (1,425/1,720) NWE and 72% (144/210) non-NWE eli-
gible patients in cohort II reached transplantation. The
increase in reaching transplantation was statistically sig-
nificant for both NWE and non-NWE patients (P=0.001
and P=0.007, respectively) in the two cohorts, but not
between NWE and non-NWE patients in cohort II. Overall
NWE patients were transplanted with better matched
donors (Figure 2), and cord blood as the source of
hematopoietic cells was significantly more frequent in
non-NWE patients. Fifteen patients in both cohorts were
transplanted with a mismatched family donor (haplo-
identical), because the chosen donor (and back-up donor if
identified) was no longer available. Overall, 240 patients
received hematopoietic cells from a back-up donor
(n=234) or a back-up cord blood unit (n=6), because the
initial chosen donor was no longer available: 70 patients in
cohort I (9.3% of NWE and 5.5% of non-NWE patients)
and 170 patients in cohort II (9.8% of NWE and 7.8% of
non-NWE patients).
Discussion 
In the last decade, substantial investments14 resulted in
an increase of the worldwide hematopoietic progenitor
cell donor pool and improvement of the quality of donor
HLA typing. However, the availability of alternative
donors, especially for patients of non-European descent15,16
remains concerning. Currently, for a Dutch NWE patient a
median number of 71 potentially matched donors are list-
ed, often allowing selection for non-HLA characteristics
(e.g., age, gender, cytomegalovirus status) that may
improve transplant outcome. In contrast, we found that
the number of potentially matched donors for our non-
NWE patients remained low: a median number of seven
UD per patient. We addressed the question of whether the
above-mentioned developments resulted in a higher per-
centage of transplants for Dutch patients. Overall, we
observed that the percentages of patients reaching trans-
plantation among both NWE and non-NWE patients in
the period 2007-2012 were higher than those in the search
period before 2007. However, the probability of identify-
ing a 10/10 matched donor for non-NWE patients has not
improved, while a significant advantage for NWE patients
has become apparent (Table 3). The probability of finding
a CBU with at least a 4/6 match increased over time for
non-NWE patients, but here also the degree of matching
appeared significantly less optimal than that for the NWE
patients in our study. Thirty percent of non-NWE patients
received cord blood grafts, compared to 10% of NWE
patients. Cord blood is currently increasingly used in
patients with very poor risk, acute leukemia, needing an
immediate transplant after having obtained remission, or
children with inborn errors, other than hemoglo-
binopathies.12,17 CBU are almost instantly available and
require less stringent HLA matching criteria, but are asso-
ciated with a higher rate of graft failure and delayed
hematopoietic recovery.18,19 Studies have suggested that
the outcome of cord blood grafting is better when the
CBU contains higher numbers of cells, or when double
CBU grafts, and/or better HLA-C matched grafts are
used.20-24 While allele level matching was recently found to
be associated with better transplant outcomes, high reso-
lution typing for HLA-A-B-C and DRB1 would probably
show 8/8 matching in only 10% of recipient/cord blood
pairs.25 Requiring a higher level of matching for cord blood
will result in fewer matching units, in particular for non-
NWE patients.
The global donor inventory
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Figure 2. Match-grade of donors for NWE and non-NWE patients reaching transplantation (RT). Match-grade was unknown for 52 (8.7%) NWE patients in cohort I
(2001-2006), 84(5.9%) NWE patients in cohort II (2007-2012), and 5 (3.5%) non-NWE patients in cohort II (2007-2012).
Matching for HLA-DPB1 is currently not mandatory in
Dutch transplant protocols. The likelihood of being DPB1-
matched is approximately 20%, while approximately
50% permissive HLA-DPB1 mismatches would lower
transplant mortality.26 DPB1 selection might be considered
in the future, but will be less feasible for non-NWE
patients given the restricted numbers of available donors
allowing no choices.   
Gragert et al. described a theoretical model based on
population genetics for calculating the likelihood of find-
ing a well-matched UD or CBU for patients of different
ethnic background in the USA.15 Donor availability, incon-
sistent typing results and donor medical eligibility were
taken into account. Their model is based on donor and
cord blood data in the BeTheMatch registry itself, repre-
senting approximately 50% of the global inventory. They
calculated a more than 95% likelihood of identifying an
UD/CBU for both white and African-American patients,
which is possibly an overestimate. Using 100% of the
global inventory,1 we found an acceptable UD/CBU with
a match-grade of at least 7/8 for 95% of NWE patients and
82% of non-NWE patients in the Netherlands. The clinical
“real life” nature of our study may explain the difference,
in that we searched for actual patients instead of conduct-
ing a theoretical exercise. The assumption that the donor
population represents a true reflection of the patient pop-
ulation might overestimate the probability of finding an
acceptable UD/CBU, in particular for patients with differ-
ent ethnic backgrounds. 
Population heterogeneity is present across the conti-
nents, but there are also unique HLA combinations at a
national level, probably originating from former colonial-
ism and more recent global migration. Cord blood offers
the opportunity for a reasonable alternative as a less mis-
matched graft, and ethnic minorities are generally willing
to donate cord blood to a public bank. However, a mis-
matched donor or CBU is not always an acceptable alter-
native. In this light, preliminary results of recent and ongo-
ing studies indicate that the role of extended family (or
haploidentical) donors could become clearer in the future. 
All patients for whom no donor was found in our study
had one or more rare alleles, uncommon HLA-B-C/DRB1-
DQB1 associations, or a combination of these, often orig-
inating from a mixed racial background. A similar obser-
vation was reported by Testi et al.,27 who identified a 9/10-
or 10/10-matched donor for 75% of their 315 patients,
who had a high frequency allele. In contrast Grubic et al.28
reported having found a 9/10- or 10/10-matched donor for
95% of 105 Croatian patients, but their cohort only con-
sisted of patients who were actually transplanted. The
genetic heterogeneity of a population apparently also
plays a role.
A weakness of our study is that the proportions of non-
NWE patients in both cohorts (13% and 11%) were small
and so confounding factors are possible. However, we
have no indication that the findings were influenced by
factors such as relapse, untimely referral, more with-
drawals, or financial aspects. Unfortunately, the propor-
tion of donors from ethnic minorities in the various donor
registries is not recorded.29
In more recent years, the significantly shorter search time,
observed for both NWE and non-NWE patients, may be a
reason for fewer cancellations. The cancellation rate, due to
clinical deterioration of the patient after a donor had been
found, preventing the patient from undergoing transplanta-
tion, was approximately 30% in the period 1991-2000,12
and only 10% in the years after 2007. This demonstrates
the importance of time, in particular in adult patients with
high-risk leukemia.30-32 Future complete, high-resolution
HLA typing and provision of additional donor characteris-
tics could theoretically minimize the length of a search to a
single day,33,34 and probably further reduce the rate of trans-
plant cancellations due to relapsed malignancies. This,
however, may not help non-NWE patients, since the limit-
ed number of registered, available and suitable non-NWE
donors in the national and international registries35-38 high-
lights the need for strategic recruitment of both UD and
CBU,39 and  for methods to prevent untimely opt-out of
donors, in particular those from ethnic minorities.40
Targeted donor recruitment, with personal and written
native speaker support, and through social media, is being
increasingly practiced.41 Furthermore, addressing miscon-
ceptions about donation add to donor commitment, and
improve chances for all patients, but in particular non-NWE
patients, to receive optimal allogeneic stem cell grafts.40 The
subject is on the agenda of registries united in the World
Marrow Donor Association.
Conclusions
Improved efficiency of searches for hematopoietic stem
cell donors is associated, overall, with more NWE and
non-NWE patients reaching their intended transplanta-
tion. However, we conclude from this large retrospective
study that the increase of the global inventory and the
major efforts and investments to improve the search
process have resulted in a strong benefit mainly for NWE
patients. For non-NWE patients, the probability of identi-
fying a well-matched UD has not increased over time and
non-NWE patients more often rely on CBU as an alterna-
tive source of hematopoietic stem cells. In addition, the
match-grade for both UD and CBU is less optimal for
non-NWE patients. In concordance with others, our find-
ings in successive cohorts of non-NWE patients are strong
confirmation of the need to expand the global inventory,
focusing on donors and grafts from underrepresented eth-
nicities.
S.M. van Walraven et al.
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